Patents by Inventor Qiudong JIANG

Qiudong JIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • JAK KINASE INHIBITOR PHARMACEUTICAL COMPOSITION
    Publication number: 20230042525
    Abstract: A JAK kinase inhibitor pharmaceutical composition, containing (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide or a pharmaceutically acceptable salt thereof and a co-processed excipient, such as cellulose-lactose. The present invention has good stability, dissolution and bioavailability, and the preparation process thereof is simple and convenient.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 9, 2023
    Inventors: Honglei XI, Qiudong JIANG, Hao CHEN
  • Pharmaceutical JAK kinase inhibitor and diethylene glycol composition for topical administration and preparation method therefor
    Patent number: 11241378
    Abstract: A pharmaceutical composition for topical administration and a preparation method therefor are described. In particular, a pharmaceutical composition comprising (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and diethylene glycol monoethyl ether is described.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: February 8, 2022
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Honglei Xi, Qiudong Jiang
  • PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION AND PREPARATION METHOD THEREFOR
    Publication number: 20200276109
    Abstract: A pharmaceutical composition for topical administration and a preparation method therefor are described. In particular, a pharmaceutical composition comprising (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and diethylene glycol monoethyl ether is described.
    Type: Application
    Filed: November 19, 2018
    Publication date: September 3, 2020
    Inventors: Honglei XI, Qiudong JIANG